PATENT CLAIM ANALYSIS

Application Number: 15780384
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-02
Patent Classification: ["424", "489000"]

Abstract:
The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer, which is a divalent metal salt, in a molar ratio of stabilizer to conjugate of 1:1 to 20:1. A dosage form of this type ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use.

Claim (Index 3):
The stable dosage form as claimed in  claim 1 , wherein magnesium or calcium salts are used as the divalent metal salt.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 93.0
- Lexical Diversity: 2.03279
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14968481', '14063951', '10742453', '12413805', '11377650']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7024619471475955
- 35 USC 102 Novelty (BERT): 0.5325535522611426
- Combined Prediction Score: 0.6854711076589501
- Mean Citation Score: 209.251042
- Max Citation Score: 216.00108
- Similarity Product: 94.9433481923032

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test